These innovative compounds represent a significant advancement in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in lowering blood glucose https://mollyihdo513916.bloggactif.com/40551546/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide